News
PSTX
9.50
0.00%
0.00
Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win
Seeking Alpha · 01/09/2025 15:26
Poseida Therapeutics Undergoes Merger and Delisting Changes
TipRanks · 01/08/2025 14:18
Deals of the day-Mergers and acquisitions
Reuters · 01/08/2025 11:14
Roche Finalizes Tender Offer for $1.5B Poseida Biopharma Deal
TipRanks · 01/08/2025 10:14
Roche to close $1.5B acquisition of Poseida Therapeutics
Seeking Alpha · 01/08/2025 07:43
BRIEF-Roche Purchases Shares Of Poseida Therapeutics, Inc. In Tender Offer
Reuters · 01/08/2025 06:17
*Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer
Dow Jones · 01/08/2025 06:15
*Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday
Dow Jones · 01/08/2025 06:12
After Hours Most Active for Jan 7, 2025 : SANA, T, NVDA, INTC, GETY, WIMI, SNAP, AAPL, PSTX, VZ, MDT, SARO
NASDAQ · 01/07/2025 21:24
Weekly Report: what happened at PSTX last week (1230-0103)?
Weekly Report · 01/06/2025 09:07
More
Webull provides a variety of real-time PSTX stock news. You can receive the latest news about Poseida Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PSTX
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.